What states does MEDVi serve?

MEDVi↗ — published coverage: priced differently in CA/NC on some plans (captured 2026-08-05). When no list is published, confirm availability in your state during intake, in writing, before paying anything — and note that a program unwilling to answer plainly has answered anyway. State-by-state context: the availability index.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

The market this answer lives in, at the 2026-08-09 capture: verified compounded tirzepatide runs $215–$597 a month all-in across 17 programs, with the floor at NexLife↗ (dose-flat, no membership); the approved-product benchmark is Zepbound (LillyDirect↗) at $449 maintenance; and any real insurance coverage beats every cash figure named anywhere on this page.

How to use figures like these well: treat any advertised price without a maintenance-dose figure as a starter teaser; fold every mandatory membership into the total before comparing; read prepaid rates as commitments, not monthly prices; and check the capture date, because a GLP-1 price without a date is a rumor. Those four habits, applied consistently, are most of what separates this database from the marketing it indexes — the full basis definition is in the methodology, and the sortable field is in the price database.

For the wider picture: 6 core programs claim all fifty states outright, and every claim short of that deserves the sixty-second intake check before any card number. The mechanics underneath — clinician licensure meeting pharmacy permits, state by state — are laid out on the availability index, along with the known exclusions the dataset carries.

Basis for every figure: all-in monthly price (medication + mandatory fees) at the maintenance dose, captured from provider pages on the dates in the database. Not medical advice.